This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Table of Contents Sr# Headings 1 Introduction: The Power of Marketing Networks 2 What Are Marketing Networks? 3 The Importance of Marketing Networks in Pharma 4 Building Healthcare Professional (HCP) Networks 5 Patient Advocacy Groups: A Trusted Connection 6 Digital Marketing Networks in Pharma 7 Branded Campaigns and Marketing Networks 8 Overcoming Challenges in Marketing Networks 9 The Role of Data in Strengthening Networks 10 Future Trends in Marketing Networks 11 Practical Tips for Pharma Ma
Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom from the Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.
As we approach the end of 2024, First Opinion is publishing a series of essays on the state of AI in medicine and biopharma. Get a group of primary care physicians together, and there’s a pretty good chance they will start talking about the potential of AI scribes to reduce documentation burden and improve the clinician-patient office interaction.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The MOVe-NOW study will assess the investigational oral antiviral using a different formulation than what is currently approved under an emergency use authorization.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we see a federal agency change its tune on patent thickets, likely because of the incoming administration. Also, a cool mouse study, and a new fund from Atlas Venture.
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. 2024 was another record year for health data breaches, according to a STAT analysis of records from the federal health department’s Office for Civil Rights.
While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Health officials investigating a disease outbreak in a remote region of the Democratic Republic of the Congo may not have laboratory results that could shed some light on the cause until Saturday, according to the head of the country’s National Public Health Institute. Dieudonné Mwamba, the agency’s director general, said Thursday that it appears that the outbreak, which is receiving growing international attention, is respiratory in nature, with most cases reporting fever, co
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Two years ago, Bain and Company forecasted ma | Nontraditional providers will account for about one-third of the primary care market in 2030, according to Bain and Company. Payer-owned primary care, population-focused models and advanced primary care providers are all poised for growth.
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Amazon has added digital musculoskeletal care company Hinge Health to its health conditions program, a service it rolled out in January to help connect customers with virtual care benefits. | Amazon has added digital musculoskeletal care company Hinge Health to its health conditions program, a service it rolled out in January to help connect customers with virtual care benefits.
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a federal appeals court. | The U.S. Court of Appeals for the Federal Circuit sided with a prior ruling that denied Novartis' motion seeking an injunction to prevent MSN's generic rival from launching.
The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.
The American Society of Hematology (ASH) Annual Meeting and Exposition will include the latest news and clinical trial updates in the hematology field.
Jerome Adams, former US surgeon general, discusses the importance of receiving recommended vaccines against influenza and COVID-19 for health care personnel.
Sacituzumab tirumotecan (sac-TMT; Kelun Pharmaceutical, Merck) is currently being studied to treat non-small cell lung cancer (NSCLC) in the TroFuse-004 and TroFuse-009 trials.
Discover how the NHS can optimise extra funding by balancing budget allocation with a focus on mindset and strategic choices to improve patient care and organisational efficiency.
Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production footprint in North Carolina. | Amgen is laying out $1 billion to build a second drug substance facility in Holly Springs, North Carolina. Together with Amgen’s existing facility in the town, the company’s investments in Holly Springs are slated to create a total of 370 new jobs.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content